StockData
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Maze Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$29.70+2.17 (+7.88%)

Close on Oct 19, 2026

Market cap
$1.75B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026After market close–––
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026After market close$20.00M––
Q4 FY2025
Ended Dec 31, 2025
Mar 25, 2026Before market open–$-0.65–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025After market close–$-0.66–
Q2 FY2025
Ended Jun 30, 2025
Aug 12, 2025After market close–$-0.77–
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025After market close–––
Q4 FY2024
Ended Dec 31, 2024
Mar 31, 2025Before market open–$-18.32–

Press releases

Announcements Maze Therapeutics filed with the SEC